Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.21.1
Basis of Presentation and Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 15 Months Ended
Dec. 11, 2020
Jan. 07, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Mar. 31, 2021
USD ($)
segment
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Basis of Presentation and Significant Accounting Policies                            
Reverse stock split conversion ratio 0.1429                          
Accumulated deficit               $ 138,179,663   $ 138,179,663 $ 130,647,485      
Net loss               7,623,140 $ 6,373,420          
Cash, Cash Equivalents, and Short-term Investments               132,000,000   132,000,000        
Derivative warrant liability               $ 42,481   42,481 $ 33,779      
Number of operating segments | segment               1            
Goodwill                            
Goodwill, Impairment Loss               $ 0   $ 0        
Revenue Recognition                            
Revenue               538,645 $ 901,880          
Allowable expenses incurred under NIH grant               $ 200,000            
Maximum                            
Revenue Recognition                            
Amount awarded from NIH grant   $ 224,713                        
Pelican Therapeutics, Inc.                            
Basis of Presentation and Significant Accounting Policies                            
Ownership interest in subsidiary               85.00%   85.00% 85.00%      
Pelican Therapeutics, Inc.                            
Basis of Presentation and Significant Accounting Policies                            
Business Acquisition, Percentage of Voting Interests Acquired                       85.00% 80.00% 80.00%
Revenue Recognition                            
Amount awarded from CPRIT grant             $ 15,200,000              
Pelican Therapeutics, Inc. | Maximum                            
Revenue Recognition                            
Amount awarded from CPRIT grant           $ 15,200,000                
Grant revenue | Pelican Therapeutics, Inc.                            
Revenue Recognition                            
Revenue               $ 13,600,000            
Grant receivable               $ 1,500,000   $ 1,500,000        
Grant revenue | First tranche | Pelican Therapeutics, Inc.                            
Revenue Recognition                            
Revenue         $ 1,800,000                  
Grant revenue | Second tranche | Pelican Therapeutics, Inc.                            
Revenue Recognition                            
Revenue       $ 6,500,000                    
Grant revenue | Third tranche | Pelican Therapeutics, Inc.                            
Revenue Recognition                            
Revenue     $ 5,400,000